In cancer, “indolent” means slow-growing. An indolent cancer is one that grows so slowly it may never cause symptoms or threaten your life. The National Cancer Institute defines it simply as “a type of cancer that grows slowly,” but the practical meaning goes deeper than that: some indolent cancers are so sluggish they would never be detected without screening, and many never require treatment at all.
If you’ve seen this word on a pathology report or heard it from a doctor, here’s what it actually means for you and how it shapes the way different cancers are managed.
How Indolent Cancers Differ From Aggressive Ones
The key difference is speed. An aggressive tumor might double in size in a matter of weeks or months. Indolent tumors can take years to grow noticeably. In a lung cancer screening study from the University of Pittsburgh, indolent tumors had a median doubling time of 752 days, roughly two years. Aggressive stage I cancers in the same study doubled in a median of about 285 days. That’s nearly a threefold difference in growth rate.
Indolent tumors also tend to have low metabolic activity, meaning the cells aren’t consuming energy at the rapid pace seen in fast-growing cancers. On imaging scans that measure metabolic activity, indolent tumors barely register above normal background tissue. This combination of slow growth and low metabolic activity is what makes many of these cancers unlikely to spread or cause harm.
Growth isn’t always steady, though. Some indolent cancers stay dormant for years and then accelerate. This is why the word “indolent” describes the current behavior of a cancer, not a permanent guarantee. Monitoring over time is what confirms whether a tumor truly remains slow-moving.
Cancers Most Often Called Indolent
Several well-known cancer types frequently fall into the indolent category:
- Low-grade prostate cancer. Prostate cancers with a Gleason score of 6 or less (Grade Group 1) are considered well-differentiated and low-grade. These are among the most common indolent cancers, and many men live their entire lives without them ever progressing.
- Follicular lymphoma. This is the most common indolent blood cancer. Low-grade follicular lymphoma has a 5-year overall survival rate of about 87% and a 10-year disease-specific survival rate of roughly 87% as well, meaning most deaths in this group are from other causes, not the lymphoma itself. Certain subtypes, like follicular lymphoma of the duodenum, rarely progress or need therapy.
- Other indolent lymphomas. Marginal zone lymphoma and lymphoplasmacytic lymphoma (also known as Waldenström macroglobulinemia) are also classified as indolent. Marginal zone lymphomas can appear in many different organs, including the stomach, thyroid, lungs, skin, and eye area.
- Papillary thyroid microcarcinoma. Very small papillary thyroid cancers are often so slow-growing that the 2025 American Thyroid Association guidelines include active surveillance as an accepted alternative to surgery for select low-risk cases.
- Ductal carcinoma in situ (DCIS). Up to 80% of DCIS lesions in the breast are considered indolent and would never progress to invasive breast cancer during a person’s lifetime.
- Certain lung cancers found on screening. Small, early-stage lung adenocarcinomas detected through low-dose CT scans are sometimes indolent. In the Pittsburgh screening study, nearly all indolent lung cancers were adenocarcinomas, and most appeared as non-solid nodules on imaging.
What “Indolent” Looks Like on a Pathology Report
You won’t always see the word “indolent” written directly on a report. Instead, pathologists use related language that points to the same thing. Terms like “low-grade,” “well-differentiated,” and “low proliferation index” all signal that a tumor’s cells look relatively normal and are dividing slowly. In prostate cancer, a Gleason score of 6 is the classic marker. In lymphomas, the specific subtype name (follicular, marginal zone) already implies indolent behavior.
If you’re reading your own report and unsure, look for the grade. Cancer grading systems rate how abnormal cells look under a microscope. Grade 1 or “low-grade” typically corresponds to indolent behavior. Higher grades suggest faster growth and more aggressive potential.
Why Indolent Cancers Often Aren’t Treated Right Away
Because these cancers grow slowly, immediate treatment isn’t always the best option. Treating a cancer that would never cause harm exposes you to side effects (pain, fatigue, sexual dysfunction, surgical risks) without a meaningful benefit. This is the core problem of overtreatment, and it’s particularly relevant for cancers found through routine screening.
Instead, many indolent cancers are managed through one of two conservative approaches. Active surveillance involves regular testing designed to catch any sign of progression early enough to still treat with the intent to cure. For low-grade prostate cancer, this typically means periodic blood tests every six months and biopsies at scheduled intervals, sometimes supplemented with MRI. The goal is to delay or avoid treatment entirely while keeping a close watch.
Watchful waiting is a less intensive approach. It skips the regular biopsies and imaging and instead simply monitors for symptoms of advanced disease. This strategy is more common in older patients or those with other significant health conditions, where the burden of frequent testing outweighs the benefit. Studies comparing the two strategies find that active surveillance extends life more than watchful waiting, particularly for patients whose disease carries a somewhat higher risk of spreading. The tradeoff is that active surveillance sometimes leads to treatment (and its side effects) that watchful waiting would have avoided.
When an Indolent Cancer Needs Treatment
The shift from watching to treating usually happens when there are signs the cancer is picking up speed. Depending on the cancer type, that could mean a tumor is growing faster on imaging, blood markers are rising, the cancer’s grade has increased on a repeat biopsy, or you’re developing new symptoms like unexplained weight loss, pain, or swollen lymph nodes.
In follicular lymphoma, for example, many patients go years without needing any treatment. Therapy begins when the disease starts causing problems: enlarged lymph nodes that press on organs, declining blood counts, or symptoms that affect daily life. Some patients with very localized disease can be treated once and remain in remission for years.
For DCIS of the breast, active surveillance trials are currently testing whether low-risk cases can safely skip surgery altogether. The rationale is straightforward: if 80% of these lesions would never become invasive, most women are being treated for something that wouldn’t have harmed them.
Indolent Does Not Mean Harmless
It’s important not to equate “indolent” with “nothing to worry about.” An indolent cancer is still cancer, and a small percentage of indolent tumors do eventually transform into something more aggressive. Follicular lymphoma can transform into a fast-growing diffuse large B-cell lymphoma. Some low-grade prostate cancers are reclassified as higher-grade on subsequent biopsies. Tumor growth can follow an unpredictable pattern, staying flat for years and then accelerating.
The practical takeaway is that “indolent” describes a cancer’s current pace, not its destiny. It means you likely have time on your side, that aggressive treatment may not be necessary right now, and that careful monitoring is a medically sound strategy rather than neglect. For many people, an indolent cancer diagnosis means living with cancer rather than fighting it, sometimes for decades, with no impact on lifespan.